Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascul...(ls of plasma and urinary isoprostanes CR...),Health

Trial 203 was a Phase 2, placebo-controlled study evaluating 40mg of SYI-2074 administered three times daily for two days in diabetic patients undergoing angioplasty. The primary endpoint of the study was reduction of the amount of heart muscle enzyme (CK-MB) released from the heart as a consequence of the procedure. Results showed that there was no significant reduction in CK-MB, which indicates that the normal damage to heart muscle following an angioplasty occurred during the procedure regardless of the administration of SYI-2074.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit inflammation related to oxidative stress. It currently plans a program in psoriasis with its lead compound. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes. It is also developing a kit to measure CML, another potential cardiovascular risk marker.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failu
'/>"/>